BioNTech and partner Pfizer - as well as rival Moderna - at the time scrambled to build a heavy-duty messenger RNA manufacturing network with dozens of external partners from scratch to produce COVID vaccines, in a technology that previously had no commercial application.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/qJA3O4z
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» BioNTech to invest $43 mln in German facility for mRNA vaccine building block
https://ift.tt/2H98ixp
No comments:
Post a Comment